Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,153
archived clinical trials in
Gout

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lexington, KY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Louisville, KY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Owensboro, KY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Owensboro, KY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Paducah, KY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Baker, LA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Baker, LA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lafayette, LA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lafayette, LA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Mandeville, LA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Mandeville, LA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Metairie, LA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Biddeford, ME
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Biddeford, ME
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Columbia, MD
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Columbia, MD
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Frederick, MD
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Frederick, MD
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Oxon Hill, MD
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Brockton, MA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Brockton, MA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Fall River, MA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Fall River, MA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Buckley, MI
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Buckley, MI
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Detroit, MI
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Kalamazoo, MI
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Biloxi, MS
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Biloxi, MS
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Olive Branch, MS
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Olive Branch, MS
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Hazelwood, MO
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Hazelwood, MO
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Washington, MO
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Washington, MO
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Billings, MT
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Missoula, MT
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Bellevue, NE
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Bellevue, NE
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lincoln, NE
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Omaha, NE
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Reno, NV
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lodi, NJ
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lodi, NJ
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Teaneck, NJ
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Brooklyn, NY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Endwell, NY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Endwell, NY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Manhasset, NY
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Columbiana, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Columbiana, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Greensboro, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Greenville, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Greenville, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Hickory, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Raleigh, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Salisbury, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Salisbury, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Wilmington, NC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Fargo, ND
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Chagrin Falls, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Chagrin Falls, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Cleveland, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Mentor, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Mentor, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Perrysburg, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Perrysburg, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Toledo, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Wadsworth, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Wadsworth, OH
Click here to add this to my saved trials